CytoDyn Inc (OTCPK:CYDY)
$ 0.1351 -0.00065 (-0.48%) Market Cap: 143.01 Mil Enterprise Value: 172.09 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 32/100

Cytodyn Inc COVID-19 Coronavirus Treatment Clinical Data Update Transcript

Apr 18, 2020 / NTS GMT
Jack Marks;Nader
Wall Street Reporter - Moderator

Good afternoon, everybody, and welcome to Wall Street Reporter's next Super Stock live stream for today, April 17, 2020. We're very proud to bring you a very special presentation from CytoDyn titled on as many of you have been following since August, the stock has done tremendously, the company has reported incredible progress.

And obviously, there's a very topical a presentation for today. As you know, the stock is up significantly and with CytoDyn's impressive pipeline, this could be just the beginning. So today, we have a lot of people on the call. So I'm going to skip my usual remarks. We'll get right to it.

The format for today is simple. Nader Pourhassan, the CEO of CytoDyn is going to speak, then we're going to engage in a panel discussion with Dr. Bruce and Jay, and then we'll open up for Q&A. Hopefully, we'll have time to answer the questions.

We've got about 70 questions. I don't know if we'll have time, but with that being said everybody up, please welcome Dr. Pourhassan. Nader, take it away.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot